Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992).
Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992).
复制标题
猫接种部位和未接种部位发生的纤维肉瘤的比较：239 例（1991-1992 年）。
DOI：
10.2460/javma.1994.205.10.1425
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
John M. Gliatto
中科院分区：
文献类型：
--
作者：
Mattie J. Hendrick;Frances S. Shofer;Michael H. Goldschmidt;Jean C. Haviland;Scott H. Schelling;Stephen J. Engler;John M. Gliatto
将样本发送给兽医，这些兽医在1991年1月1日至1992年6月30日期间将猫的纤维肉瘤提交给宾夕法尼亚大学和塔夫茨大学兽医学院的外科病理学服务。问卷调查项目包括显著性、FeLV和猫免疫缺陷病毒状态、肉瘤部位、接种部位、使用的疫苗、治疗、肿瘤的生物学行为和最终结局。连续数据采用Student t检验，分类数据采用卡方检验，生存率估计采用对数秩检验。比较接种部位（VS）肿瘤和非接种部位（NVS）肿瘤的猫的结果，我们确定VS肿瘤发生在年轻的猫中，并且比NVS肿瘤大。虽然VS肉瘤具有生物学侵袭性，并且比NVS肉瘤更常发生再发展，但未检测到转移，并且VS肿瘤猫的存活时间长于NVS肿瘤猫。猫在注射多种类型的疫苗（单独或联合给药）后发生疫苗接种部位肉瘤。在VS组接受单次疫苗接种的猫中，37%接受狂犬病疫苗接种，33%接受猫病毒性鼻气管炎/杯状病毒/泛白细胞减少症病毒接种，30%接受FeLV疫苗接种。与NVS肿瘤猫相比，VS肿瘤猫更有可能接种FeLV疫苗，而接种狂犬病疫苗的可能性更小。尽管某些制造商生产的疫苗最常用于患有VS和NVS肉瘤的猫，但人们认为这可能代表了营销实践和品牌知名度。（250字处删节）
Questionnaires were sent to veterinarians who had submitted a fibrosarcoma from a cat to the surgical pathology services of the veterinary schools of the University of Pennsylvania and Tufts University between Jan 1, 1991 and June 30, 1992. Questionnaire items included signalment, FeLV and feline immunodeficiency virus status, site of sarcoma, vaccination site, vaccines used, treatment, biologic behavior of the tumor, and final outcome. Data were analyzed, using Student's t-test for continuous data, chi 2 test for categoric data, and log-rank test for survival estimates. Comparing results for cats with vaccination-site (VS) tumors and nonvaccination-site (NVS) tumors, we determined that VS tumors developed in younger cats and were larger than NVS tumors. Although VS sarcomas were biologically aggressive and redeveloped more often than NVS sarcomas, metastasis was not detected, and cats with VS tumors survived longer than cats with NVS tumors. Vaccination-site sarcomas developed in cats after injection of many types of vaccines, administered singularly or in combination. Of the cats in the VS group administered a single vaccine, 37% were given rabies, 33% were given feline viral rhinotracheitis/calicivirus/panleukopenia virus, and 30% were given FeLV vaccines. Cats with VS tumors were more likely to have received FeLV vaccine and less likely to have received rabies vaccine than those with NVS tumors. Although vaccines produced by certain manufacturers were used most often in cats with VS and NVS sarcomas, it was believed that this probably represented marketing practices and brand popularity.(ABSTRACT TRUNCATED AT 250 WORDS)